We have discovered a vast, expanded universe of novel proteins encoded by the human genome. In analyzing these proteins, we elucidate their respective biological functions, refining our understanding of the molecular underpinnings of human biology and disease. Armed with this knowledge, we’re aiming to create breakthrough medicines for a multitude of diseases.

Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases.

Brainomix has revolutionized medical imaging with an AI-powered platform that automates validated imaging biomarkers—improving both diagnosis and treatment decisions.

Early brings early disease detection to the comfort of our homes with devices that are accurate, easy to use and beautiful. This allows prompt medical treatment and radically improves chances of survival.

Building the world’s first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences.

Ignota Labs applies deep learning to bioinformatics and cheminformatics datasets to solve drug safety issues, rescuing promising but failing drugs and bringing new life to abandoned projects and new hope to patients.